TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
In this research study, investigators are testing if a dose-increasing strategy for
abemaciclib will have less side effects and be better tolerated than the standard dosage of
abemaciclib for participants with early-stage high-risk hormone receptor positive breast
cancer.
The names of the study drugs involved in this study are:
- Abemaciclib (CDK4 and CDK6 inhibitor)
- Tamoxifen (Selective estrogen receptor modulator)
- Anastrozole/Letrozole (Non-steroidal aromatase inhibitors)
- Exemestane (steroidal aromatase inhibitor)
- LHRH (Gonadotropin-releasing hormone agonist, or Luteinizing hormone-releasing hormone
agonist)